- Home
- AGIO vs NFJ Comparison
AGIO vs NFJ Comparison
Compare AGIO & NFJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AGIO | NFJ |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | AGIO | NFJ |
|---|---|---|
| Price | $27.95 | $13.78 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $36.63 | N/A |
| AVG Volume (30 Days) | ★ 881.5K | 223.5K |
| Earning Date | 02-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.01% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $54,028,000.00 | N/A |
| Revenue This Year | $104.62 | N/A |
| Revenue Next Year | $125.15 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 48.03 | N/A |
| 52 Week Low | $22.24 | $10.45 |
| 52 Week High | $46.00 | $12.86 |
Technical Indicators
Market Signals| Indicator | AGIO | NFJ |
|---|---|---|
| Relative Strength Index (RSI) | 54.94 | 60.74 |
| Support Level | $26.05 | $13.62 |
| Resistance Level | $29.93 | $13.81 |
| Average True Range (ATR) | 1.18 | 0.12 |
| MACD | 0.10 | 0.00 |
| Stochastic Oscillator | 62.47 | 66.04 |
Price Performance
Historical ComparisonAbout AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About NFJ Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest
Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. The primary investment objective of the company is to seek current income and gains, with a secondary objective of long-term capital appreciation. The fund pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.